Operational Update
Summary by AI BETAClose X
9 November 2026
Oxford BioDynamics Plc
(“OBD” or the “Company” and together with its subsidiaries the “Group”)
Operational Update
Oxford BioDynamics Plc (AIM: OBD, the Company), the 3D Genomics Company, provides the following operational update ahead of its annual report and accounts for the year ended 30 September 2026.
Highlights
- Continued growth in EpiSwitch PSE volumes, milestone of 500 tests in a month reached in September 2026
- Approximately 4,200 PSE tests sold in the year ended 30 September 2026, 124% increase year-on-year
- FY26 revenue of £1.65m (FY25: £1.10m)
- Cash and cash equivalents of £7.4m at 30 September 2026
- Appointment of Richard Compton as CEO announced 30 June 2026
- First agreement for EpiSwitch Orion with pharmaceutical partner, with Johnson & Johnson, announced 5 November 2026
- EpiSwitch Orion early access programme underway ahead of full release at the Festival of Genomics in January 2027, with proof-of-principle proposals issued to leading genomics programmes
- Results from blinded colorectal cancer study shared with a multinational healthcare partner; Company will engage with multiple potential partners on funding the next stage of EpiSwitch NST
Note – all financial information subject to audit
Strategic priorities
The Group’s strategy focuses on generating revenue from three areas: Discovery, Development and Diagnostics.
Diagnostics
Approximately 4,200 EpiSwitch PSE tests were sold in the year ended 30 September 2026, representing an increase of 124% on the prior year. More than 500 tests were ordered in a single month for the first time in September 2026. Revenue for the year is expected to be £1.65m, in line with market expectations and arising almost exclusively from PSE. The number of clinics ordering the test and the number making repeat orders both grew. The current run-rate is more than double that of one year ago, with a further record monthly order total in October 2026.
In the US, the Group expects continued increases in PSE volumes, in line with the current growth trajectory. OBD has reorganised its US team to prepare for higher throughput, in-house or through partnering, and to improve reimbursement efficiency.
In the UK, results from a blinded colorectal cancer study, run on a small cohort of samples with a multinational healthcare partner, have been shared with the partner and the study unblinded. The Company expects to engage with multiple potential partners before determining the preferred development route for EpiSwitch NST.
Efforts to secure a partner-funded evidence programme for EpiSwitch CiRT are continuing. As previously noted, the Board plans to partner its pipeline tests, and potentially its existing tests, with suitable third parties.
Discovery and Development
Discovery includes commercial projects using EpiSwitch Orion and EpiSwitch Explorer. Following Orion’s first commercial agreement announced in July 2026, on 5 November the Company announced its first agreement for Orion with a pharmaceutical partner, a biomarker discovery project in inflammatory bowel disease for Johnson & Johnson.
EpiSwitch Orion predicts 3D regulatory architecture from existing genome data, linking non-coding disease variants to the genes they regulate. Ahead of its full release at the Festival of Genomics & Biodata in London in January 2027, the Company is working with several key groups through an early access programme.
Since the start of November, the Company has issued proof-of-principle proposals to leading programmes in Europe, North America, the Middle East and Asia; a second wave, on complex disease and polygenic risk prediction, is underway.
Several programmes have agreed initial steps. The Company is also developing cell-type-specific prediction, allowing a variant to be assessed in the tissue where the disease gene acts.
Development builds on Discovery work, creating bespoke EpiSwitch assays that help partners to improve patient stratification in phase 2 clinical trials. Phase 2 clinical trials are where most drug development programmes fail, but those that select patients using a biomarker have been shown to have higher success rates. Using a custom EpiSwitch biomarker in a simple blood test can reduce the cost of patient recruitment and give a higher likelihood of success.
Financial position
Following the Company’s successful £9.15m equity fundraise in August 2026, cash and cash equivalents at 30 September 2026 were £7.4m, with a further £0.5m of proceeds from the fundraising being received after that date.
Wherever possible, the cost of external contractors and new staff is being funded by reducing other costs. Alongside the US reorganisation, the Company has terminated or paused certain advisory contracts and expects to continue to review other costs over the coming months.
Management change
The Board was pleased to announce the appointment of Richard Compton as Chief Executive Officer in June 2026. Richard brings 25 years of commercial leadership experience in the sector to the role, most recently as Senior Vice President for Sales and Commercial Operations at Oxford Nanopore Technologies plc.
Outlook
The Company remains focused on driving PSE volume growth, converting its commercial pipeline and managing cash carefully as it works toward its next milestones. Audited results for the year ended 30 September 2026 are expected to be announced in mid-December 2026.
Investor presentation
Richard Compton, CEO, will present at the Yellowstone Advisory Private Investor Evening on 11 November 2026 at the offices of SEC Newgate in London. Investors should register for the event at: https://www.yellowstoneadvisory.com/events and questions about the evening should be emailed to info@yellowstoneadvisory.com.
Richard Compton, Chief Executive Officer of OBD, said:
"Since the summer fundraise, our focus has been on execution. August, September and October were successive record months for PSE, and our current run-rate is more than double that of a year ago.
“We are pleased to have signed our first agreement with a pharma customer for EpiSwitch Orion, with Johnson & Johnson. We are seeing significant early responses to the proposals shared with more than one hundred Principal Investigators and leading genomics programmes worldwide.
“At the same time, we have reorganised our US team and reduced costs so that resources are directed towards the opportunities most likely to deliver commercial results in the near term.
“Our priority across the business is to convert the science into revenue. After my first 100 days, I am confident about the Company’s prospects and appreciative of the support that investors new and old have given me."
-Ends-
For further information please contact:
|
Oxford BioDynamics Plc Richard Compton, CEO Paul Stockdale, CFO
|
+44 (0)1865 518910 |
|
Singer Capital Markets – Nominated Adviser and Broker Alex Bond / Russell Cook / Anastassiya Eley
|
+44 (0)20 7496 3000 |
|
Merlin Partners LLP – Joint Broker Matthew Clarke
|
+44 (0)20 3973 3678 |
|
Camarco – Financial PR Marc Cohen / Sukaina Virji / Fergus Young / Tomisin Ibikunle |
+44 (0)20 3757 4980 OBDFinancial@camarco.co.uk
|
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD), the 3D genomics company, is an international biotechnology company that unlocks actionable clinical and biological insight from genomic data that pharma, biotech and research partners already hold. Its lead platform, EpiSwitch® Orion, is a cloud-based, AI-powered 3D genomics discovery platform that transforms standard and legacy whole genome sequencing datasets into discovery insights in hours rather than months, revealing the 90-95% of disease-associated variants that sit in non-coding regions and are invisible to traditional NGS and GWAS approaches. The platform is built on the world's largest curated 3D genomics knowledgebase — over 1.5 billion data points and 15 million high-confidence genomic connections validated across 18,000+ patient samples in more than 40 diseases.
That same underlying science also powers OBD's two commercially available clinical blood tests, EpiSwitch PSE (Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test), and a pipeline of new tests in oncology, neurology, inflammation, hepatology and animal health.
Since inception, the Company has participated in more than 40 collaborations with pharmaceutical and academic partners, including Pfizer, EMD Serono, Genentech, Roche and Biogen. The Company's headquarters and UK laboratories are in Oxford, UK, with US operations in Maryland and a reference laboratory in Penang, Malaysia.
OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit www.oxfordbiodynamics.com, X (@OxBioDynamics) or LinkedIn.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 2 hours ago Luceco
- 2 hours ago Helios Towers
- 3 hours ago Wise Class A
- 3 hours ago EDX Medical Group Plc
- 3 hours ago Naked Wines